A detailed history of Hantz Financial Services, Inc. transactions in Myriad Genetics Inc stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 344 shares of MYGN stock, worth $2,628. This represents 0.0% of its overall portfolio holdings.

Number of Shares
344
Previous 11 3027.27%
Holding current value
$2,628
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 04, 2025

BUY
$3.84 - $8.84 $1,278 - $2,943
333 Added 3027.27%
344 $2,000
Q1 2025

May 12, 2025

BUY
$8.87 - $14.98 $97 - $164
11 New
11 $0

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $616M
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Hantz Financial Services, Inc. Portfolio

Follow Hantz Financial Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hantz Financial Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hantz Financial Services, Inc. with notifications on news.